Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development

Despite the existence of vaccines for SARS-CoV-2, the constant evolution of new variants and the occurrence of breakthrough infections highlight the need for new and effective antiviral approaches. We have shown that lipopeptides designed to bind a conserved region on the SARS-CoV-2 spike protein ca...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of virology Vol. 99; no. 3; p. e0215924
Main Authors:	Kuhn, Ariel J., Outlaw, Victor K., Marcink, Tara C., Yu, Zhen, Mears, Megan C., Cajimat, Maria N., Kreitler, Dale F., Cleven, Payton R., Mook, Jee Ching, Bente, Dennis A., Porotto, Matteo, Gellman, Samuel H., Moscona, Anne
Format:	Journal Article
Language:	English
Published:	United States American Society for Microbiology 18.03.2025
Subjects:	antiviral Antiviral Agents - chemistry Antiviral Agents - pharmacology COVID-19 - virology COVID-19 Drug Treatment crystal structure Editor’s Pick heptad repeats Humans inhibitors lipopeptide Lipopeptides - chemistry Lipopeptides - pharmacology MATERIALS SCIENCE peptide design SARS-CoV-2 SARS-CoV-2 - drug effects Solubility Spike Glycoprotein, Coronavirus - antagonists & inhibitors Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - metabolism Vaccines and Antiviral Agents viral fusion Virology Virus Internalization - drug effects inhibitors SARS-CoV-2 lipopeptide antiviral viral fusion crystal structure peptide design solubility heptad repeats
ISSN:	0022-538X, 1098-5514, 1098-5514
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!